Peer-reviewed veterinary case report
Heart tests in 14 dogs with lymphoma during doxorubicin chemo
By Tater, G et al.·Published in Veterinary and comparative oncology·2017·Small Animal Hospital, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Assessment of cardiac troponin I (cTnI) and tissue velocity imaging (TVI) in 14 dogs with malignant lymphoma undergoing chemotherapy treatment with doxorubicin.
- Species:
- dog
Plain-English summary
Fourteen dogs with lymphoma were treated with doxorubicin, a chemotherapy drug that can sometimes harm the heart. Researchers measured heart function and levels of a protein called cardiac troponin I (cTnI) before and after treatment to check for any heart damage. Over the course of the treatment, they found no significant changes in heart function or cTnI levels, suggesting that using doxorubicin at standard doses is safe for the heart in these dogs. This means that the dogs could receive effective treatment for their lymphoma without major heart concerns.
People also search for: dog lymphoma treatment · doxorubicin side effects in dogs · dog heart health during chemotherapy
Abstract
Doxorubicin has been shown to be cardiotoxic at high doses but is an efficacious chemotherapeutic agent in the treatment of canine lymphoma. Echocardiographic measurements and serum ultrasensitive cardiac troponin I (cTnI) levels were obtained before and after doxorubicin administration in 14 dogs diagnosed with lymphoma. The aim of this prospective study was to evaluate changes in cTnI concentrations and tissue velocity imaging (TVI) values in dogs with lymphoma undergoing chemotherapy with doxorubicin. A total of 182 cTnI and 1017 TVI measurements were performed. Standard echocardiographic parameters, tissue Doppler indices and cTnI concentrations did not differ at any time point within a 12-week cyclic combination protocol. In conclusion, the use of doxorubicin at standard doses in the treatment of canine lymphoma may not be associated with significant myocardial damage.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25664927/